Christopher Elias, Founder

Christopher Elias is a scientific leader with 27+ years of experience taking biologic and cell therapy products from research to commercialization. He specializes in analytical development, assay validation, process optimization, tech transfer, and regulatory support in demanding GMP and GLP environments. His work covers analytical strategy, product characterization, manufacturing support, and validation programs for both early-stage pipelines and commercial products.

Before founding Black Oak BioSolutions, Christopher held senior scientific leadership positions at Kolon TissueGene, Lonza, and BioReliance. Throughout his career, he has led product characterization, analytical validation, comparability assessments, stability programs, and technology transfers across multiple development and manufacturing sites. He has supported programs from early development through Biologics License Application (BLA) submissions, authoring technical documentation and regulatory responses for interactions with the FDA. Known for his collaborative approach, Christopher has partnered closely with biotechnology companies, CROs, CDMOs, and regulatory teams to solve complex scientific and operational challenges. Today, he brings that same commitment to scientific rigor, quality, and execution to every Black Oak BioSolutions engagement, helping clients advance innovative therapies toward commercialization and ultimately, to patients